Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Connect Biopharma will webcast a September 15, 2026 fireside chat for investors, with replay access available for about three months.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Connect Biopharma (CNTB) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11:30 a.m. ET.
The live webcast will be accessible through the Investors section of the company’s website, and an archived replay will remain available online for approximately 90 days after the conference.
Details
News Market Reaction – CNTB
On Sep 4, the first trading day after this news, CNTB closed 4.66% below the previous close. Argus tracked a peak move of +4.9% during that session. Argus tracked a trough of -15.1% from its starting point during tracking. Our momentum scanner recorded 24 alerts for this stock that day. Relative volume reached 20.5x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- Conference edition
- 28th annual
- H.C. Wainwright Global Investment Conference
- Presentation date
- September 15, 2026
- Fireside chat
- Presentation time
- 11:30 a.m. ET
- September 15, 2026
- Replay availability
- approximately 90 days
- Following the conference
Historical Context
-
Enrollment completion and September topline-data timing supported a positive clinical-development update.
-
Asthma enrollment completion preceded expected topline data and FDA discussions regarding a Phase 3 program.
-
Fireside chat announcement lacked operating or clinical results, preceding a negative reaction.
-
Private placement, cash runway guidance, and ongoing Phase 2 development accompanied quarterly results.
-
Interim review found no safety concerns and enrollment continued, but shares declined.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET.
The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately
For more information visit www.connectbiopharma.com.
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.